|MDACC Study No:||2013-0173 (clinicaltrials.gov NCT No: NCT01779791)|
|Title:||An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in|
Subjects with Refractory Follicular Lymphoma
|Principal Investigator:||Nathan Fowler|
|Study Description:||The goal of this clinical research study is to learn if IMBRUVICAŽ (ibrutinib) |
can help to control follicular lymphoma. The safety of this drug will also be
Ibrutinib is designed to stop a protein from working in the cells, which may
cause the cancer cells to die or stop growing.